CEL-SCI Corporation
8229 Boone Boulevard, Suite 802
Vienna, VA 22182, USA
Phone: (703) 506-9460
gdewindt@cel-sci.com
www.cel-sci.com

Company Overview

CEL-SCI completed the world's largest Phase 3 study in head and neck cancer and reported data showing a significant survival benefit with no toxicity added in patients with advanced primary squamous cell carcinoma of the head and neck (SCCHN) who received its Multikine®* immunotherapy prior to a standard of care (SOC) treatment of surgery plus radiotherapy as compared to patients who received SOC alone. Multikine reduced and eliminated tumors within 3 weeks and before surgery. The Company is preparing to file for regulatory approval through a Biologic License Application (BLA) with the U.S. Food and Drug Administration (FDA) for a patient population comprising over 200,000 annually. CEL-SCI's goal is to have the greatest impact by activating the immune system to fight cancer BEFORE surgery, radiation, and chemotherapy have damaged it, addressing the largest segment of the market—people with newly diagnosed cancer. Head and neck cancer is a multi-billion dollar global market and Multikine has received Orphan Drug designation from the FDA for this indication, SCCHN, an unmet need for which the FDA has not approved a new treatment in over 50 years. CEL-SCI has completed the commercial scale buildout of its Multikine manufacturing facility in anticipation of market demand for Multikine once it receives regulatory approval.

EQUITY OVERVIEW*

NYSE American: CVM
Stock Price: ~$3.50
Trading Volume (90 day average): 290 K
Shares Outstanding: ~ 43 M
Market Cap: ~$150 M
Cash on Hand (6/30/22): $28 M
*As of September 29, 2022

ANALYST COVERAGE

EF Hutton

PEER REVIEWED PHASE 3 PRESENTATIONS

- **American Society of Clinical Oncology (ASCO) Conference 2022**
- **European Society for Medical Oncology (EMSO) Annual Congress 2022**

UPCOMING MILESTONES

- **More presentations and data submissions to top peer reviewed scientific venues/journals**
- **FDA Biologics License Application (BLA) filing**
- **Validation of manufacturing facility**
- **Global Phase 3 study spanned 20 countries; FDA approval is expected to lead to approval in many countries**

IP & MANUFACTURING

- **Robust technological protection for Multikine in the U.S., Europe, China, and Japan**
- **73,000 sq. ft. cGMP manufacturing facility**
- **Over $100 M spent on manufacturing plant, development, and validation**

HEAD & NECK CANCER MARKET

- **890,000 new cases each year**
- **CEL-SCI's target population is 200,000+ per year**

Investment Highlights

Multikine Modulates & Mobilizes Intact Immune Response to Kill Cancer

Multikine is a copy of the pro-inflammatory cytokine immune response our bodies produce every day and is designed to empower a person's intact immune system cells to attack their own cancer. Patients are treated with Multikine right after diagnosis, before any other standard of care treatment. The goal is to help the intact immune response detect and kill the tumor and micro-metastases in order to reduce recurrence and improve overall survival. In CEL-SCI's Phase 3 study, Multikine immunotherapy produced a very significant 14.1% 5-year survival benefit (62.7% vs 48.6%) as well as a nearly 4-year overall survival benefit in the treatment arm receiving Multikine prior to surgery plus radiotherapy, as compared to the control group receiving only surgery plus radiotherapy.

Multikine Treatment Regimen Schematic

Advanced Primary Head and Neck Cancer
(*SOC=standard of care)



Proposed New 1st Line SOC* for patients receiving Surgery and Radiotherapy only

Phase 3 Trial Reports Positive Results: Preparing to File for FDA Approval

928 patients were randomized into two treatment arms determined by risk of recurrence post-surgery following National Cancer Comprehensive Network (NCCN)* guidelines. 41.2% of patients were prescribed surgery + radiation (no chemotherapy) based on NCCN guidelines, and 50.6% were prescribed surgery + chemoradiation (chemotherapy and radiation concurrently) based on NCCN guidelines. 8.2% were exclusions who did not receive radiation or chemotherapy due to doctor, family, and patient decisions. In the treatment arm that was prescribed surgery + radiation (no chemotherapy), Multikine immunotherapy produced a statistically significant 14.1% 5-year survival benefit. 62.7% of patients treated with Multikine were alive 5-years after treatment as compared to 48.6% for patients who did not receive Multikine. Importantly, 16% of Multikine patients in the radiation-only group had at least a 30% tumor reduction within a few weeks of treatment before surgery and 5 of these had their tumors completely disappear before surgery, in only 3 weeks. Patients who had a tumor response had greatly improved survival.

cGMP Manufacturing Facility for Commercial Scale Multikine Production

CEL-SCI recently completed the commercial scale buildout of its dedicated current Good Manufacturing Practice (cGMP) facility in which it manufactures Multikine®. The construction is designed to ensure the facility will be compliant with all U.S. FDA and European cGMP regulations. Production capacity has been doubled to meet anticipated market demand for Multikine once it receives regulatory approval.